Urogen pharma announces exclusive license agreement with agenus inc to advance treatment of urinary tract cancers

Urogen pharma announces exclusive license agreement with agenus inc to advance treatment of urinary tract cancers.urogen pharma - to develop and commercialize zalifrelimab with ugn-201 for high-grade non-muscle invasive bladder cancer.urogen pharma ltd - in exchange for worldwide exclusive license to agen1884 agenus will receive an upfront payment of $10 million.urogen pharma ltd - agenus may receive up to $115 million for achieving certain clinical development and regulatory milestones related to agen1884.urogen pharma ltd - agenus may receive up to $85 million upon achieving certain commercial milestones related to agen1884.urogen pharma ltd - will be responsible for all development and commercialization activities of agen1884.urogen pharma - worldwide license does not include argentina, brazil, chile, colombia, peru, venezuela.
AGEN Ratings Summary
AGEN Quant Ranking